Abemaciclib Improves Survival in Patients With Liposarcoma
Clinical Summary:
- Design/Population: The phase 3 SARC041 trial randomized patients with recurrent or metastatic dedifferentiated liposarcoma to receive abemaciclib or placebo, with crossover to open-label abemaciclib allowed after progression on placebo.
- Key Outcomes: Abemaciclib significantly improved progression-free survival compared with placebo, with an encouraging trend toward improved overall survival. Objective responses were uncommon but favored abemaciclib, and no new safety signals were observed.
- Clinical Relevance: Abemaciclib may provide a new systemic treatment option for dedifferentiated liposarcoma, a disease with limited effective therapies, supporting CDK4 inhibition as a clinically meaningful strategy in this biomarker-driven sarcoma subtype.
Mark Dickson, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discusses results from the phase 3 SARC041 trial, which randomized patients with recurrent or metastatic dedifferentiated liposarcoma to receive either abemaciclib or placebo.
Results demonstrated that abemaciclib significantly improved progression-free survival (PFS) with favorable trends toward improved overall survival (OS), and no new safety concerns. These findings support abemaciclib as a promising new therapeutic option in this patient population.
Dr Dickson presented these results during the plenary session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Source:
Dickson MA, Ballman KV, Weiss MC, et al. SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. LBA2.
